Physician profile
Daniel K Khodadadian
NPI 1336174374
$4,369.68
in general payments reported to CMS, 2019-2025
18 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 79% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.65 · 2020: $37.78 · 2021: $275 · 2022: $546 · 2023: $950 · 2024: $1,322 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,051.87 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $680.55 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $438.14 | 2022-2025 | Doctors Allergy Formula, Vyzulta, Miebo |
| Horizon Therapeutics Plc | $344.34 | 2022-2023 | Tepezza |
| Alcon Vision LLC | $304.76 | 2019-2025 | Simbrinza, Clareon |
| Abbott Laboratories | $275.00 | 2023-2024 | Freestyle Libre 3 |
| Intuity Medical INC | $219.86 | 2022 | |
| Corcept Therapeutics | $202.57 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $135.00 | 2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2023 | Cycloset |
| Glaukos Corporation | $101.14 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.43 | 2021 | |
| Sight Sciences, INC. | $68.55 | 2021-2023 | Tearcare System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $30.61 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $28.92 | 2023 | Tyrvaya |
| Dompe US, INC. | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Khodadadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.